Genomic signature explains FDG-avidity of PSMA-suppressed prostate tumors

(Society of Nuclear Medicine and Molecular Imaging) Scientists have uncovered the genomic signature to explain why 18F-FDG imaging performs better than PSMA-targeted imaging for prostate cancer patients with low or no expression of the prostate-specific membrane antigen (PSMA). In a study published in The Journal of Nuclear Medicine, researchers determined that a neuroendocrine gene signature associates with a distinct differential expression of glucose transporters and hexokinase proteins, whic...